Merck & Co. Inc. | 2013 | FY | 3

A reconciliation of total segment profits to consolidated Income before taxes is as follows:
Years Ended December 31
2013
 
2012
 
2011
Segment profits:
 
 
 
 
 
Pharmaceutical segment
$
22,983

 
$
25,852

 
$
25,617

Other segments
3,094

 
3,163

 
2,995

Total segment profits
26,077

 
29,015

 
28,612

Other profits (losses)
19

 
26

 
(11
)
Unallocated:
 
 
 
 
 
Interest income
264

 
232

 
145

Interest expense
(801
)
 
(714
)
 
(695
)
Equity income from affiliates
(159
)
 
102

 
41

Depreciation and amortization
(2,250
)
 
(2,059
)
 
(2,412
)
Research and development
(6,381
)
 
(7,126
)
 
(7,251
)
Amortization of purchase accounting adjustments
(4,690
)
 
(4,872
)
 
(5,000
)
Restructuring costs
(1,709
)
 
(664
)
 
(1,306
)
Net charge related to settlement of ENHANCE Litigation
—

 
(493
)
 
—

Arbitration settlement charge
—

 
—

 
(500
)
Other unallocated, net
(4,825
)
 
(4,708
)
 
(4,289
)
 
$
5,545

 
$
8,739

 
$
7,334

us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock